***In situ* androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral production**

Kiyoshi Ito^{1,2}, Yasuhiro Miki¹, Takashi Suzuki³, Keely May McNamara⁴ and Hironobu Sasano⁴

¹Department of Disaster Obstetrics and Gynecology, International Research Institute of Disaster Science (IRIDeS), Tohoku University, Sendai, Japan

²Department of Disaster Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan

³Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan

⁴Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan

Correspondence should be addressed to K Ito

Email
kito@med.tohoku.ac.jp

Abstract

In situ estrogen biosynthesis is considered to play pivotal roles in the development and progression of human endometrial carcinoma. However, the biological roles of androgen have remained virtually unknown. Various epidemiological studies have revealed that elevated serum androgen levels are generally associated with an increased risk of developing endometrial carcinoma; however, studies directly examining androgens in carcinoma tissues are relatively rare and reviews summarizing this information are scarce. Therefore, we summarized recent studies on androgens in endometrial carcinoma, especially focusing androgen actions and *in situ* androgen biosynthesis. Among the enzymes required for local biosynthesis of androgen, 17 β -hydroxysteroid dehydrogenase type 5 (conversion from androstenedione to testosterone) and 5 α -reductase (reduction of testosterone to dihydrotestosterone (DHT)) are the principal enzymes involved in the formation of biologically most potent androgen, DHT. Both enzymes and androgen receptor were expressed in endometrial carcinoma tissues, and *in situ* production of DHT has been reported to exist in endometrial carcinoma tissues. However, testosterone is not only a precursor of DHT production, but also a precursor of estradiol synthesis, as a substrate of the aromatase enzyme. Therefore, aromatase could be another key enzyme serving as a negative regulator for *in situ* production of DHT by reducing amounts of the precursor. In an *in vitro* study, DHT was reported to exert antiproliferative effects on endometrial carcinoma cells. Intracrine mechanisms of androgens, the downstream signals of AR, which are directly related to anticancer progression, and the clinical significance of DHT-AR pathway in the patients with endometrial carcinoma have, however, not been fully elucidated.

Key Words

- ▶ androgen
- ▶ androgen receptor
- ▶ endometrial carcinoma
- ▶ 5 α -dihydrotestosterone
- ▶ 5 α -reductase
- ▶ aromatase

Endocrine-Related Cancer
(2016) **23**, R323–R335

Introduction

Endometrial carcinoma is one of the most common female pelvic malignancies in the developed countries, and its incidence has increased. In the United States,

60,050 new cases and 10,470 deaths due to endometrial carcinoma were reported in 2016 (Siegel *et al.* 2016). It is well known that sex-steroid hormones play pivotal roles

in the development of hormone-dependent carcinoma, including prostate, breast and endometrium, and in the case of the latter, estrogen actions are well known to play important role in the development and progression of endometrial carcinoma. Results of many previously reported clinical studies demonstrated that excessive and/or prolonged exposure to unopposed estrogens increased the risk of endometrial carcinoma especially that of the endometrioid type, also known as type I endometrial carcinoma (Bokhman 1983). However, in contrast to studies regarding estrogens, the possible impact of androgen actions on endometrial carcinoma has largely remained unknown. Therefore, we summarize the recent studies regarding the effects and/or actions of androgens in endometrial carcinoma in this review.

Serum androgen and increased risk of developing endometrial cancer

The great majority of endometrial cancers arise during the postmenopausal period. Circulating estrogen levels decline steeply after menopause but testosterone levels remained unchanged during the menopausal years (Burger *et al.* 2000). Over the age of 65 years, total testosterone levels decline with age until 80, alongside free testosterone levels did not vary by age (Cappola *et al.* 2007). All androgens in postmenopausal women are suggested to be made locally in peripheral target tissues according to the mechanism of local intracrine formation of steroids. The contribution of ovarian production of circulating androgenic precursors and thus potentially supporting this local intracrine metabolism of steroids is underlined by studies showing serum dehydroepiandrosterone (DHEA); the inactive precursor hormone of androgens is higher in intact compared with oophorectomized women (Labrie *et al.* 2011, Labrie 2015), and several studies reported that the serum levels of androgens between ovarian and peripheral veins were significantly different between early and late menopausal women, suggesting that the production of androgens by the ovaries could persist even 10 years after the onset of menopause, but may subsequently decline (Fogle *et al.* 2007, Maruoka *et al.* 2014). Therefore, the degree and duration to which postmenopausal ovaries remain a viable androgen-producing organ is still controversial and not fully understood.

Several investigators reported that elevated serum levels of androgen, including DHEA, DHEA sulfate (DHEAS), androstenedione (A4), testosterone and 5 α -dihydrotestosterone (DHT), were significantly associated with an increased risk of developing

endometrial carcinoma (Potischman *et al.* 1996, Kaaks *et al.* 2002, Lukanova *et al.* 2004, Allen *et al.* 2008, Audet-Walsh *et al.* 2011). Potischman and coworkers also reported that high circulating levels of A4 were associated with 2.8-fold increased risks of developing endometrial cancer among postmenopausal women, following the adjustment for other factors (Potischman *et al.* 1996). These authors subsequently concluded that circulating levels of A4 yielded most significant and consistent correlation with the risks of developing endometrial carcinoma compared with those of estrone (E₁), estradiol (E₂) and E₁-sulfate (E₁S) (Potischman *et al.* 1996). Kaaks and coworkers also reviewed numerous epidemiological studies and concluded that endometrial carcinoma risks were increased among pre- and postmenopausal women associated with elevated plasma A4 and testosterone (Kaaks *et al.* 2002). Thereafter, two prospective studies have reported discrepant results for the association of cancer risk with serum androgen levels. A multicenter prospective study also demonstrated that elevated circulating levels of A4 and DHEAS were positively associated with endometrial cancer risk, although free testosterone did not correlate with an increased risk among postmenopausal women (Lukanova *et al.* 2004). In contrast, elevated circulating levels of total and free testosterone were positively associated with endometrial cancer risk, although A4 and DHEAS were not necessarily correlated with increased risks among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition Study (EPIC) (Allen *et al.* 2008). Recently, using highly specific and sensitive validated methods based on liquid chromatography/electrospray tandem mass spectrometry (LC-MS/MS), Audet-Walsh and coworkers compared the levels of 18 circulating steroid hormones in 126 postmenopausal cases of endometrial carcinoma with 110 cases of healthy postmenopausal women and to investigate how these hormonal levels could be possibly related to clinical characteristics (Audet-Walsh *et al.* 2011). Most hormones, including DHEA, DHEAS, A4, testosterone and DHT, were significantly elevated in endometrial carcinoma cases compared with healthy controls. These particular epidemiological findings clearly indicate that elevated serum androgen levels increase the risks of developing endometrial carcinoma at least in postmenopausal women.

The impact of polycystic ovary syndrome (PCOS), a well-known common endocrine disorder affecting 5–8% of women with reproductive age and associated with menstrual irregularity, elevated androgen and polycystic ovaries (Azziz *et al.* 2004), has also been examined in relation to endometrial cancer risk,

and given its association with increased androgenicity may give important clues to the link between androgens and this malignancy. A recent systemic review and meta-analysis revealed that women with PCOS have significant increased risks of endometrial carcinoma (odds ratio 2.79) compared with those without PCOS. In addition, the risks of women with PCOS increased further for endometrial carcinoma (odds ratio 4.05) less than 54 years of age (Barry *et al.* 2014). PCOS and endometrial carcinoma shared many of the similar risk factors (obesity, diabetes, anovulation, inflammation etc.), but elevated androgens themselves may be considered the pivotal factor for endometrial carcinoma risk. However, data on serum levels of androgen and risks of developing endometrial carcinoma among premenopausal women are yet to be completely established. To the best of our knowledge, only two prospective studies have been reported to date (Allen *et al.* 2008, Clendenen *et al.* 2016). Clendenen and coworkers recently reported that no significant association was detected between circulating androgens and risks of developing endometrial carcinoma before menopause, which was consistent with the results of other prospective study (Clendenen *et al.* 2016). However, it is entirely true that androgen concentrations obtained in these studies were measured by classical radioimmunoassay (Allen *et al.* 2008, Clendenen *et al.* 2016) with the inherent limitations involved in this methodology. Thus while these studies provide important preliminary evidence, future studies employing gold standard techniques of steroid assays would be ideal in resolving the question of circulating androgens and risks of developing endometrial carcinoma in premenopausal women.

Despite the information above suggesting a relationship between androgens and endometrial cancer, risk studies directly examining the effects of androgens on endometrial cancer cells have had mixed results in contrast to the consistent stimulation of proliferation observed with estrogens in the same models (Tuckerman *et al.* 2000, Braunstein 2007). In addition, in a more physiological setting, short-term exogenous testosterone treatment of postmenopausal women did not stimulate endometrial proliferation and counteract the proliferative effects induced by E_2 (Zang *et al.* 2007, Shufelt & Braunstein 2009). Therefore, the biological link between the increased endometrial carcinoma risks associated with elevated levels of androgen in circulation and androgen actions on endometrial cells is not well characterized or understood. Several investigators reported that elevated plasma levels of androgens resulted in increased tissue estrogen levels through their aromatization in peripheral

or local tissues, including adipose, breast and endometrial carcinoma tissues (Sasano & Harada 1998, Bélanger *et al.* 2002, Somboonporn *et al.* 2004). Therefore, androgens may be locally converted into estrogens by adipose tissue and/or hiding small neoplastic cells and neoplastic cells could possibly grow rapidly in the presence of locally produced estrogens especially in postmenopausal women. Estrogen-dependent neoplasms such as breast and endometrioid endometrial carcinoma, in which *in situ* conversions from serum androgens to biologically active estrogens occur and are biologically important, are therefore considered as 'intracrine'-dependent malignancies.

In situ androgen metabolism and synthesis

Intracrinology

Recently, a great deal of focus has been given to the importance of intratumoral metabolism and synthesis of biologically active steroids in various systems. This is attributable to the documented importance of the interactions of various enzymes in the pathogenesis and progression of various human hormone-dependent neoplasms, including breast and endometrial carcinoma. This complex system, shown in a simplified version in figure one, means that enormous local control over the types and amounts of steroids produces and specific to one tissue is possible. Results of numerous studies have demonstrated increased tissue estrogen content in human breasts, compared with serum and/or normal non-neoplastic tissues of the same patients (van Landeghem *et al.* 1985, Pasqualini & Chetrite 1999, Chetrite *et al.* 2000). In these studies, the tissue concentrations of E_1 and E_2 were generally several times higher than those detected in the plasma or in the area of the normal breast tissues of the same postmenopausal patients, despite markedly low levels of circulating estrogens. In contrast to breast carcinoma cases, there is limited data regarding tissue estrogen concentrations in endometrial carcinoma tissues (Bonney *et al.* 1986, Vermeulen-Meiners *et al.* 1986, Naitoh *et al.* 1989, Berstein *et al.* 2003). Berstein and coworkers examined 78 endometrial carcinomas and detected higher concentrations of E_2 in carcinoma tissue specimens compared with macroscopically normal endometrium (Berstein *et al.* 2003). Our findings (Ito 2005, Ito *et al.* 2006) were generally consistent with those of other studies demonstrating higher E_2 levels associated with carcinoma. These results suggest that intratumoral estrogen metabolism and synthesis are pivotal in the progression of endometrial carcinoma, although the

available data of sex-steroid hormone concentrations were all obtained by classical radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA) and not by the modern gold standard methods of mass spectrometry. This distinction may be important as the classical methods of RIA and ELISA have been the standard methodology to analyze steroid hormones; however, these methods harbor several problems, including sensitivity and specificity/cross-reactions (Rauh 2012). On the other hand, LC-MS/MS is highly specific and sensitive to validated methods, which could measure highly specific hormones from very small amounts of the sample (Rauh 2012).

The status of intratumoral androgen concentration has been less frequently explored than that of estrogen in breast and endometrial carcinoma. Among the androgens, DHT binds with the highest affinity to androgen receptor (AR), and together with testosterone promotes AR transcriptional activity, while A4 and DHEA have extremely low binding affinity for AR (Avancès et al. 2001). Potent androgen DHT concentrations were significantly higher in breast carcinoma tissues than in plasma (Recchione et al. 1995), and the tissue concentration of DHT was three-fold higher in ductal carcinoma *in situ* of the breast compared with the non-neoplastic breast (Shibuya et al. 2008). The analysis of serum DHT concentration in the patients of endometrial carcinoma was reported (Audet-Walsh et al. 2011), but not in the cases of DHT concentration in endometrial tumor tissues. We recently measured the tissue and serum concentrations of testosterone and DHT in 31 endometrioid endometrial adenocarcinoma tissue and 5 normal endometrium samples using LC-MS/MS methods (Tanaka et al. 2015) with the advantages mentioned above. This study revealed that a markedly elevated DHT tissues/serum concentration ratio was detected in endometrioid endometrial adenocarcinoma tissues compared with that in normal endometrial tissues (8.0-fold). This finding also indicated that local production of DHT in endometrioid endometrial adenocarcinoma could be similar to that of breast carcinoma. Among the enzyme system required for local biosynthesis of androgen, 17 β -hydroxysteroid dehydrogenase type 5 (17 β -HSD5: conversion from A4 to testosterone) and 5 α -reductase (5 α -Red: reduction of testosterone to DHT) are the principal enzymes involved in the formation of biologically active androgen, DHT. The examination of these responsible enzymes in endometrial carcinoma tissues is very important to obtain the better understanding of the significance of androgen in endometrial carcinomas.

17 β -HSD5

17 β -HSDs are key enzymes involved in the formation of biological active sex steroids, including testosterone, E₁ and E₂. The reduction of A4 is known to result in the production of testosterone mainly by 17 β -HSD5 (Dufort et al. 1999). 17 β -HSD5, a reductive 17 β -HSD, is a member of aldo-keto reductase superfamily and formally termed AKR1C3, whereas the others are members of the short-chain alcohol dehydrogenase (Deyashiki et al. 1995). 17 β -HSD5 is expressed in various peripheral tissue, liver, prostate, ovary and has been also reported in prostate and breast carcinoma tissues (Luu-The et al. 2001, Vihko et al. 2004, Suzuki et al. 2010).

Increased 17 β -HSD5 mRNA and protein expression were reported in endometrial carcinoma tissues compared with normal endometrium (Rižner et al. 2006, Smuc & Rizner 2009). However, one group reported weaker protein expression of 17 β -HSD5 in hyperplastic and cancerous endometrium compared with normal proliferative endometrium (Zakharov et al. 2010) and no significant difference of mRNA expression between cancerous and normal endometrial tissues was detected in other groups (Cornel et al. 2012, Sinreih et al. 2013). In our previous study, 17 β -HSD5 immunoreactivity was detected in 18/36 (50%) and 71/103 (69%) cases of endometrial hyperplasia and endometrioid endometrial carcinoma, respectively. However, 17 β -HSD5 immunoreactivity was detected only in 5/26 (19%) and 5/20 (25%) cases of proliferative and secretory phase endometria, respectively (Ito 2005, Ito et al. 2006). 17 β -HSD5 immunoreactivity in endometrioid endometrial carcinoma was significantly higher than that of proliferative and secretory phase and endometrial hyperplasia. Due to the inconsistent and limited data on the available studies of 17 β -HSD5 expression, further investigation is warranted.

5 α -reductase

5 α -reductase (5 α -Red) is an enzyme responsible for the conversion of testosterone to a most potent androgen, DHT. This enzyme is considered to be an important regulator of local actions of androgens. Two 5 α -Red isoenzymes, Types 1 and 2 (e.g. 5 α -Red1 and 5 α -Red2), have been cloned and characterized in humans (Russell & Wilson 1994). In 18 normal cycling human endometria, 5 α -Red1 and 5 α -Red2 were both detected in the cytoplasm of epithelial cells, with weak or focal perinuclear immunolocalization patterns through all phases of the menstrual cycle (Ito et al. 2002). 5 α -Reds mRNA and protein were also

expression by tumor–stromal interactions. In addition, a significant correlation was detected between aromatase expression in stromal cells and poor prognosis in the patients with endometrial carcinoma (Segawa *et al.* 2005), although several studies reported that aromatase expression was demonstrated in carcinoma and stromal cells together (Segawa *et al.* 2005, Jongen *et al.* 2009, Che *et al.* 2014). It is very important to consider *in vitro* stromal–carcinoma cell interactions when studying aromatase expression *in vitro*. We previously examined whether estrogen biosynthesis in the tumor microenvironment promoted endometrial carcinoma or not. In order to study the contribution of stromal cells to estrogen signaling pathways in endometrial carcinoma, we examined reporter cells stably transfected with the estrogen response element (ERE) fused to the destabilized green fluorescent protein (GFP) gene (Matsumoto *et al.* 2008). In this system, the ERE of carcinoma cells was activated to a variable extent by intratumoral stromal cells isolated from endometrial carcinoma. When testosterone was added as a substrate for aromatase, the GFP expression levels increased. Thereafter, these effects were variably inhibited by aromatase inhibition. These results indicated that GFP expression is driven by estrogen synthesized by aromatase in the endometrial cancer stromal cells. In addition, in order to further confirm the local biosynthesis of estrogens and tumor–stromal interactions on aromatase activity, endometrial carcinoma cell lines were cocultured with stromal cells isolated from endometrial carcinomas, and aromatization activity was measured using LC-MS/MS (Takahashi-Shiga *et al.* 2009). We also examined the effects of aromatase inhibitors on cell proliferation. Aromatase activity was significantly higher in the coculture with carcinoma cell lines and stromal cells than in each monoculture, respectively. Cell proliferation was significantly inhibited in carcinoma cells treated with aromatase inhibitors compared with control cultures. Recently, Che and coworkers also reported that aromatase expression in stromal, but not in carcinoma epithelium cells, was associated with interleukin 6 expression in epithelial cells of carcinomas by immunohistochemistry, which were subsequently confirmed also using laser capture microdissection/real-time RT-PCR in endometrial carcinoma tissues (Che *et al.* 2014). Their results did demonstrate the presence of the activation of a positive feedback loop in which interleukin 6 stimulated by E₂ in endometrial carcinoma epithelial cells induced aromatase expression in stromal cells, thereby promoting intratumoral E₂ synthesis. These findings above did confirm the importance of carcinoma–stromal cells

interaction in the process of induction of aromatase in endometrial carcinoma tissues, and demonstrated that aromatase is a key enzyme in the local biosynthesis of estrogen in endometrial carcinoma as well as breast carcinoma. However, further investigation should be required to clarify the association between the expression of aromatase and intratumoral DHT concentration in endometrial carcinoma.

DHT is catalyzed to 3 α and 3 β androstenediol, which are relatively inactive, by 3 α -keto-reductase (AKR1C) and 3 β -keto-reductase (AKR1C2), respectively. The enzyme of AKR1C2 has the predominant catalytic efficiency. Rižner & Penning (2014) reviewed the possible roles of AKR1 enzymes in human steroid metabolism and alluded on the possibility of AKR1C gene expression in endometrial carcinoma. However, AKR1C1 and AKR1C2 mRNA expression in cancerous endometrium did not differ significantly to that in adjacent control normal tissue (Smuc & Rizner 2009, Sinreih *et al.* 2013). Therefore, it is unlikely that AKR1C1 and AKR1C2 serve as negative regulators of *in situ* production of DHT in endometrial carcinoma.

Androgen receptor and androgen action in endometrial cancer

Structure of androgen receptor

Androgens mediate their effects through the androgen receptor (AR). AR belongs to the nuclear receptor subfamily 3 group C gene 4 (NR3C4) and also to the nuclear receptor superfamily for steroid hormones. DHT binds with the highest affinity to AR, and together with testosterone, promotes AR transcriptional activities (Avancès *et al.* 2001). A polymorphic CAG repeat in exon 1 of the AR gene is well known to encode a polyglutamine tract and to increase the length of CAG repeat, which is also well known to be associated with decreased transactivation activities (Chamberlain *et al.* 1994). Of particular interest, a statistically significant inverse association has been reported between increased CAG repeat length and endometrial carcinoma risk in case-control studies (McGrath *et al.* 2006, Ashton *et al.* 2010), although controversies exist (Yang *et al.* 2009). On the other hand, Yang and coworkers evaluated 36 sex hormone-related genes using a tagging approach in a population-based case-control study of 417 endometrial carcinoma cases and reported that the possible evidence of the correlation with endometrial cancer risk could be the common genetic variation in

AR (Yang *et al.* 2010). All of these results above did suggest that variant structures of AR played pivotal roles in the risks of developing endometrial carcinoma.

Androgen receptor expression

In the nonmalignant endometrium, AR was reported to be expressed in the endometrium throughout the menstrual cycle (Mertens *et al.* 2001, Apparao *et al.* 2002, Ito *et al.* 2002, Marshall *et al.* 2011, Gibson *et al.* 2014). The status of AR immunoreactivity in stromal cells is higher than that of epithelial AR throughout the menstrual cycle (Apparao *et al.* 2002). In our previous study, AR immunoreactivity was detected in the nuclei of both epithelial and stromal cells (Ito *et al.* 2002). AR immunoreactivity was also detected in the nuclei of 60–70% of stromal cells in the proliferative phase, while negative at functional is of endometrium in the secretory phase. AR immunoreactivity was detected in the nuclei of around 5–15% of epithelial cells in the secretory phase, while negative or very weak in the proliferative phase. Endogenous and exogenous androgens should have the ability to alter endometrial function through AR expression. For example, in women with PCOS, who generally exhibit chronic hyperandrogenism, exhibited elevated endometrial AR immunoexpression has been documented compared with normal fertile control (Apparao *et al.* 2002) suggesting the effects on androgens in changing the intracrine environment of these tissues. In a similar vein, albeit circumstantial, correlation between endometrial AR expression and serum androgens levels has also been demonstrated in the context of obesity and weight loss. Serum androgens are reported to be positively correlated with BMI (Allen *et al.* 2008) and abdominal fat accumulation (Cao *et al.* 2013), but in asymptomatic morbidly obese women in response to interventions that reduce abdominal fat and/or BMI such as bariatric surgery and weight loss, AR immunoexpression dropped significantly in response to these interventions (Argenta *et al.* 2014) perhaps hinting at the correlation between serum androgens and endometrial AR expression.

The expression of AR in endometrial carcinoma has been detected in several studies (Horie *et al.* 1992, Sasaki *et al.* 2000, Ito *et al.* 2002, Qiu *et al.* 2014, Tanaka *et al.* 2015). The number of cases was small ($n=4$), but Horie and coworkers reported that all specimens of endometrial carcinoma tissues examined expressed AR (Horie *et al.* 1992). On the other hand, Sasaki and coworkers reported that AR was not detected in 79% of endometrial carcinomas, although their cases included several

unknown histological types (Sasaki *et al.* 2000). Qiu and coworkers recently reported AR-highly expressing cells in 50 of 76 cases (66%) of endometrial carcinoma (Qiu *et al.* 2014). In our previous study, AR immunoreactivity was detected in the nuclei of carcinoma cells and the number of positive cases was 39/44 (89%) (Ito *et al.* 2002). In the great majority of cases, carcinoma tissue homogenates did also have mRNA expression. Thereafter, AR expression was recently reported in 92 of 122 cases (82%) of endometrioid endometrial carcinoma (Tanaka *et al.* 2015). These studies all demonstrated that AR was expressed in the great majority of endometrial carcinoma, especially in endometrioid type.

Androgen action

The possible impact of androgen actions and the pivotal roles of androgen signaling through its receptor in endometrial carcinoma have not yet been clarified. DHT is nonaromatizable androgen and not converted to estrogen. DHT acts most markedly as an androgen through the AR pathway. Hackenberg and coworkers and Hackenberg & Schulz first demonstrated the inhibition of cell proliferation in human endometrial carcinoma cell line, MFE-296 cells, by DHT (Hackenberg *et al.* 1994, Hackenberg & Schulz 1996). Lovely and coworkers subsequently reported that DHT can act as antiestrogens through inhibiting the alkaline-phosphatase enzymatic activity in a dose-dependent manner, using hormonally responsive cell lines (a well-differentiated endometrial adenocarcinoma cell lines, Ishikawa) (Lovely *et al.* 2000). AR protein expression in Ishikawa cell lines was subsequently reported to be up-regulated by DHT or E_2 and to be inhibited by the antiandrogen, hydroxyflutamide or bicalutamide, or medroxyprogesterone acetate (MPA) based on Western blot analysis (Apparao *et al.* 2002). These studies consistently demonstrated that androgens had the important ability to inhibit cell proliferation through DHT-AR pathway in endometrial carcinomas *in vitro*. In contrast, *in vivo* animal model study demonstrated that DHT excess neither significantly suppressed nor increased the growth rate of well-differentiated human endometrial carcinoma implants in the nude mice, although AR expression in tumor tissues were not examined (Legro *et al.* 2001).

In breast carcinoma, DHT is considered to be locally produced mainly via 5 α -Red1. In addition, immunohistochemical analysis showed that patients with positive for both AR/5 α -Red1 demonstrated significant correlations with decreased risk of recurrence

and improved prognosis for overall survival, and AR/5 α -Red1 status was an independent prognostic factor (Suzuki *et al.* 2007). AR/5 α -Red1 double-negative status was significantly correlated with worse prognosis even in triple-negative invasive breast carcinoma, which is defined as the absence of ER, PR and human epidermal growth factor receptor 2 (HER2) expression in tumor cells (McNamara *et al.* 2013). In addition, the absence of intratumoral androgenic enzymes, both 5 α -Red1 and 17 β -HSD5, was significantly associated with adverse clinical outcome in patients with invasive lobular carcinoma of the breast (Yoda *et al.* 2014). All of these findings above did indicate that DHT could inhibit the cell proliferation through DHT-AR pathway and influence the eventual clinical prognosis of the patients with breast cancer.

Using the logic and evidence of studies in the breast as guidelines, it then becomes clear that it is very important to analyze the correlation between the status of AR and 5 α -Reds and clinicopathological findings to further clarify the clinical significance of DHT-AR pathway in endometrial carcinoma. AR expression was significantly inactivated by hypermethylation of the AR gene CpG islands in human endometrial carcinoma compared with normal endometria, using pairs of carcinomatous and normal samples from 28 patients (Sasaki *et al.* 2000). All carcinoma samples from advanced stage did demonstrate only methylated AR alleles and immunoexpression of AR negative, although about half of the cases from early stage harbored these alleles. In addition, Rodríguez and coworkers had genotyped both CAG and GGN repeats from 204 cases of endometrial carcinoma tissues and revealed that the presence of short CAG or GGN repeats of the AR genes in a tumor specimens was correlated with a favorable conditions of prognostic values in endometrial carcinoma (Rodríguez *et al.* 2006). Shortening each repeat has been considered to increase either the amount of AR protein (GGN) or its activity (CAG) (Chamberlain *et al.* 1994, Ding *et al.* 2005). In our recent study using 86 endometrioid endometrial adenocarcinoma samples with immunohistochemical analysis, the AR-positive status was significantly correlated with progression-free survival (PFS), but not with endometrial carcinoma-specific survival (ECSS) in endometrial carcinoma patients (Tanaka *et al.* 2015). 5 α -Red1-positive status was significantly associated with both PFS and ECSS in those patients. In addition, AR/5 α -Red1 double-negative status was significantly correlated with worse PFS and ECSS, when these patients were divided into four groups, according to the status of AR and 5 α -Red1, such as AR/5 α -Red1 double positive, positive/negative, negative/positive and

double negative status, respectively (Tanaka *et al.* 2015). In addition, Kamal and coworkers recently reported that AR was expressed in postmenopausal endometrial epithelium and their subsequent loss in endometrial carcinoma was significantly associated with disease-free survival (Kamal *et al.* 2016). Those results consistently demonstrated that a lack of androgen action in intratumoral levels is correlated with a poor prognosis in the patients, and androgen signaling exerts anticancer effects through DHT-AR pathway in endometrial carcinoma. Results of our study also indicated that it was important to evaluate both AR status and 5 α -Red1, the latter serving as a surrogate marker of intratumoral DHT production, for understanding the effect of androgenic signaling on carcinoma progression (Miki *et al.* 2015, Tanaka *et al.* 2015).

Androgen action from the viewpoint of therapeutic target

In order to understand the anticancer effects through DHT-AR pathway, it is necessary to analyze the downstream signals of AR. However, such DHT-induced genes have remained largely unknown in endometrial carcinoma. Qiu and coworkers recently demonstrated that the mRNA expression of AR target gene (XBP1, MYC, ZBTB16, and UHRF1) increased after treatment with DHT in the human endometrial carcinoma cell line MFE-296 cells, although the roles of those target genes has still remained virtually unknown (Qiu *et al.* 2014). In addition, the possible roles of androgen-induced genes in endometrial carcinoma have been recently elucidated. In breast carcinoma cells, DHT predominantly exerted antiproliferative effects on mitogenic effects of estrogens (Lapointe & Labrie 2001). Those inhibitory effects were correlated with increased levels of cyclin-dependent kinase inhibitor p21 and/or p27 (Lapointe & Labrie 2001, Greeve *et al.* 2004). Takagi and coworkers also reported that E₂-mediated proliferation was significantly inhibited by DHT in T-47D breast carcinoma cells, which express AR and ER (Takagi *et al.* 2010). This proliferation was also associated with an increase in 17 β -HSD2 expression level and 17 β -HSD2 was induced by DHT in a dose-dependent manner. In addition, local E₂ concentration was inversely associated with 17 β -HSD2 status in breast carcinoma tissues. It is well known that 17 β -HSD2 preferentially catalyzes testosterone and E₂, to A4 and E₁, respectively (Wu *et al.* 1993). However, 17 β -HSD2 expression was reported to be significantly associated with decreased risk to develop late relapse of breast carcinoma (Gunnarsson *et al.* 2001, 2005).

In addition, significant positive association was reported between the status of androgenic enzymes, 17 β -HSD5 and 5 α R1, and 17 β -HSD2, and in particular, 17 β -HSD2 expression was inversely correlated with tumor size in invasive lobular carcinoma of the breast (Yoda et al. 2014). These findings above all indicated that DHT acted, at least partly, through the up-regulation of 17 β -HSD2 and decreasing local E₂ concentration, and finally played the pivotal roles involved in antiproliferative effects in breast cancer. We have recently reported that 17 β -HSD2 immunoreactivity was detected in 37% of endometrial carcinoma cases and correlated with 17 β -HSD2 enzymatic activity and expression of 17 β -HSD2 mRNA (Utsunomiya et al. 2001). In normal endometrium, 17 β -HSD2 immunoreactivity was present at all the cases of secretory phase, but not at any endometrial mucosa of proliferative phase. 17 β -HSD2 mRNA expression was consistently detected in endometrial carcinoma compared with adjacent normal endometrium at menopausal status in several studies (Lépine et al. 2010, Cornel et al. 2012, Sinreih et al. 2013). Therefore, the enzyme of 17 β -HSD2 should play an important role to modify the balance of estrogen production in not only breast but also endometrial carcinoma. If DHT is involved in the modulation of *in situ* estrogen metabolism by stimulating the expression of 17 β -HSD2, DHT could be one of the important candidates as a new endocrine-related agent in endometrial carcinoma. Further investigation should be required to clarify the therapeutic roles of DHT in endometrial carcinoma.

As we mentioned above, aromatase is a negative regulator for *in situ* production of DHT. Aromatase-inhibitory therapeutic agents are considered the most effective endocrine therapies in postmenopausal patients with estrogen-dependent breast carcinoma (Bulun et al. 2005). Of particular interest, intratumoral concentration of DHT in breast carcinoma tissue was significantly higher in the patients treated with exemestane, the aromatase inhibitor, than in those who did not receive this therapy (Takagi et al. 2010). This result indicated that aromatase-inhibitory agents could cause increased concentrations and actions of DHT, in conjunction with estrogen deprivation in breast carcinoma. In contrast, there remain some controversies as to whether or not aromatase-inhibitory agents could be effective in the patients with endometrial carcinoma. Previous Gynecologic Oncology Group Study (GOG) could not possibly demonstrate distinct clinical efficacy with aromatase inhibitor treatment (Rose et al. 2000). Thereafter, a prospective phase II trial for fulvestrant was conducted in 53 recurrent

or persistent endometrioid endometrial carcinoma (Covens et al. 2011). Patients were stratified into subsets of ER-positive and -negative patients. In ER-positive patients, 3, 13 and 29% cases demonstrated a complete or partial response and stable disease, although no cases were associated with either a complete or a partial response, and 18% demonstrated stable disease in ER-negative patients. Nordic Society of Gynecologic Oncology Study (NSGO) reported similar results (Lindemann et al. 2014). Thangavelu and coworkers examined the biological changes in human endometrial carcinoma tissues before and after aromatase inhibitor treatment (Thangavelu et al. 2013). Patients were randomized to receive anastrozole or placebo before definitive surgery. Treatment with anastrozole caused a marked decrement in proliferation as demonstrated by decreased Ki-67 expression. Sasano previously reported similar results using [³H] thymidine uptake or Ki-67 labeling (Sasano et al. 1999). Therefore, it is important to clarify the roles, including the possibility of application and indication, of aromatase-inhibitory drugs in hormone-receptor positive or hormone-sensitive endometrial carcinoma in postmenopausal patients. In addition, aromatase inhibitor therapy might be established as one form of endocrine treatment of endometrial carcinoma, if aromatase-inhibitory drugs cause not only estrogen deprivation but also increased antiproliferative actions of DHT. Further analysis is required to clarify the clinical importance of DHT actions in association with the therapeutic efficacy of aromatase-inhibitory drugs in endometrial carcinoma.

Summary and conclusion

Local androgens exert both direct and indirect impacts on endometrial carcinoma. Testosterone is not only a precursor of estrogen synthesis as the substrate of aromatase, but also a precursor of DHT production as the substrate of 5 α -Red enzymes. Recent studies revealed that *in situ* DHT synthesis occurred at the same time with estrogen synthesis, and DHT signaling could directly exert anticancer effects through DHT-AR pathway in endometrial carcinoma. Aromatase is a negative regulator for *in situ* production of DHT. If aromatase-inhibitory agents cause not only estrogen deprivation but also increased antiproliferative actions of DHT, combination therapy of DHT and aromatase inhibitor agents could be one of the important candidates as a new endocrine-related agent for endometrial carcinoma especially in postmenopausal patients. However, the downstream signals of AR, which are directly involved in anticancer

effects, have remained largely unknown in endometrial carcinoma. Further investigation should be required to understand the mechanisms and impacts of anticancer signaling by AR-activation for establishing the possible androgen therapies.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

Supported by Tohoku University IRiDeS Research Project (KI and YM).

Author contribution statement

K I drafted the manuscript. Y M, T S, K M M and H S edited the manuscript. All authors read and approved the final manuscript.

References

- Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, Peeters PH, Onland-Moret NC, Lahmann PH, Berrino F, et al. 2008 Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Endocrine-Related Cancer* **15** 485–497. (doi:10.1677/ERC-07-0064)
- Apparao KB, Lovely LP, Gui Y, Lininger RA & Lessey BA 2002 Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. *Biology of Reproduction* **66** 297–304. (doi:10.1095/biolreprod66.2.297)
- Argenta P, Svendsen C, Elishaev E, Gloyeske N, Geller MA, Edwards RP & Linkov F 2014 Hormone receptor expression patterns in the endometrium of asymptomatic morbidly obese women before and after bariatric surgery. *Gynecologic Oncology* **133** 78–82. (doi:10.1016/j.ygyno.2013.12.005)
- Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U & Scott RJ 2010 Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk. *Cancer Epidemiology* **34** 328–337. (doi:10.1016/j.canep.2010.03.005)
- Audet-Walsh E, Lépine J, Grégoire J, Plante M, Caron P, Têtu B, Ayotte P, Brisson J, Villeneuve L, Bélanger A, et al. 2011 Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. *Journal of Clinical Endocrinology and Metabolism* **96** 330–339. (doi:10.1210/jc.2010-2050)
- Avancès C, Georget V, Térouanne B, Orio F, Cussenot O, Mottet N, Costa P & Sultan C 2001 Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens. *Molecular and Cellular Endocrinology* **184** 13–24. (doi:10.1016/S0303-7207(01)00669-4)
- Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES & Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. *Journal of Clinical Endocrinology and Metabolism* **89** 2745–2749. (doi:10.1210/jc.2003-032046)
- Barry JA, Azizia MM & Hardiman PJ 2014 Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Human Reproduction Update* **20** 748–758. (doi:10.1093/humupd/dmu012)
- Bélanger C, Luu-The V, Dupont P & Tchernof A 2002 Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. *Hormone and Metabolic Research* **34** 737–745. (doi:10.1055/s-2002-38265)
- Berstein LM, Tchernobrovkina AE, Gamajunova VB, Kovalevskij AJ, Vasilyev DA, Chepik OF, Turkevitch EA, Tsyrlina EV, Maximov SJ, Ashrafiyan LA, et al. 2003 Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. *Journal of Cancer Research and Clinical Oncology* **129** 245–249.
- Bokhman JV 1983 Two pathogenetic types of endometrial carcinoma. *Gynecologic Oncology* **15** 10–17. (doi:10.1016/0090-8258(83)90111-7)
- Bonney RC, Scanlon MJ, Jones DL, Reed MJ, Anderson MC & James VH 1986 The relationship between oestradiol metabolism and adrenal steroids in the endometrium of postmenopausal women with and without endometrial cancer. *European Journal of Cancer and Clinical Oncology* **22** 953–961. (doi:10.1016/0277-5379(86)90062-3)
- Braunstein GD 2007 Safety of testosterone treatment in postmenopausal women. *Fertility and Sterility* **88** 1–17. (doi:10.1016/j.fertnstert.2007.01.118)
- Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, et al. 2005 Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. *Pharmacological Reviews* **57** 359–383. (doi:10.1124/pr.57.3.6)
- Burger HG, Dudley EC, Cui J, Dennerstein L & Hopper JL 2000 A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. *Journal of Clinical Endocrinology and Metabolism* **85** 2832–2838. (doi:10.1210/jc.85.8.2832)
- Cao Y, Zhang S, Zou S & Xia X 2013 The relationship between endogenous androgens and body fat distribution in early and late postmenopausal women. *PLoS ONE* **8** e58448. (doi:10.1371/journal.pone.0058448)
- Cappola AR, Ratcliffe SJ, Bhasin S, Blackman MR, Cauley J, Robbins J, Zmuda JM, Harris T & Fried LP 2007 Determinants of serum total and free testosterone levels in women over the age of 65 years. *Journal of Clinical Endocrinology and Metabolism* **92** 509–516. (doi:10.1210/jc.2006-1399)
- Carneiro MM, Morsch DM, Camargos AE, Reis FM & Spritzer PM 2008 Androgen receptor and 5 α -reductase are expressed in pelvic endometriosis. *BJOG* **115** 113–117. (doi:10.1111/j.1471-0528.2007.01521.x)
- Chamberlain NL, Driver ED & Miesfeld RL 1994 The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. *Nucleic Acids Research* **22** 3181–3186. (doi:10.1093/nar/22.15.3181)
- Che Q, Liu BY, Liao Y, Zhang HJ, Yang TT, He YY, Xia YH, Lu W, He XY, Chen Z, et al. 2014 Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17 β -estradiol biosynthesis in endometrial carcinoma microenvironment. *International Journal of Cancer* **135** 282–294. (doi:10.1002/ijc.28679)
- Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F & Pasqualini JR 2000 Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. *Journal of Steroid Biochemistry and Molecular Biology* **72** 23–27. (doi:10.1016/S0960-0760(00)00040-6)
- Clendenen TV, Hertzmark K, Koenig KL, Lundin E, Rinaldi S, Johnson T, Krogh V, Hallmans G, Idahl A, Lukanova A, et al. 2016 Premenopausal circulating androgens and risk of endometrial cancer: results of a prospective study. *Hormones and Cancer* **7** 178–187. (doi:10.1007/s12672-016-0258-1)
- Cornel KM, Kruitwagen RF, Delvoux B, Visconti L, Van de Vijver KK, Day JM, Van Gorp T, Hermans RJ, Dunselman GA & Romano A 2012 Overexpression of 17 β -hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17 β -estradiol. *Journal of Clinical Endocrinology and Metabolism* **97** E591–E601. (doi:10.1210/jc.2011-2994)

- Covens AL, Filiaci V, Gersell D, Lutman CV, Bonebrake A & Lee YC 2011 Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecologic Oncology* **120** 185–188. (doi:10.1016/j.ygyno.2010.10.015)
- Deyashiki Y, Ohshima K, Nakanishi M, Sato K, Matsuura K & Hara A 1995 Molecular cloning and characterization of mouse estradiol 17 beta-dehydrogenase (A-specific), a member of the aldoketoreductase family. *Journal of Biological Chemistry* **270** 10461–10467. (doi:10.1074/jbc.270.18.10461)
- Ding D, Xu L, Menon M, Reddy GP & Barrack ER 2005 Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. *Prostate* **62** 133–139. (doi:10.1002/pros.20128)
- Dufort I, Rheault P, Huang XF, Soucy P & Luu-The V 1999 Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. *Endocrinology* **140** 568–574. (doi:10.1210/endo.140.2.6531)
- Fogle RH, Stanczyk FZ, Zhang X & Paulson RJ 2007 Ovarian androgen production in postmenopausal women. *Journal of Clinical Endocrinology and Metabolism* **92** 3040–3043. (doi:10.1210/jc.2007-0581)
- Gibson DA, Simitsidelis I, Collins F & Saunders PT 2014 Evidence of androgen action in endometrial and ovarian cancers. *Endocrine-Related Cancer* **21** T203–T218. (doi:10.1530/erc-13-0551)
- Greeve MA, Allan RK, Harvey JM & Bentel JM 2004 Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1). *Journal of Molecular Endocrinology* **32** 793–810. (doi:10.1677/jme.0.0320793)
- Gunnarsson C, Olsson BM, Stål O & Southeast Sweden Breast Cancer Group 2001 Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. *Cancer Research* **61** 8448–8451. (doi:10.1038/sj.bjc.6602375)
- Gunnarsson C, Hellqvist E & Stål O 2005 17beta-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. *British Journal of Cancer* **92** 547–552.
- Hackenberg R & Schulz KD 1996 Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. *Journal of Steroid Biochemistry and Molecular Biology* **56** 113–117. (doi:10.1016/0960-0760(95)00228-6)
- Hackenberg R, Beck S, Filmer A, Hushmand Nia A, Kunzmann R, Koch M, Slater EP & Schulz KD 1994 Androgen responsiveness of the new human endometrial cancer cell line MFE-296. *International Journal of Cancer* **57** 117–122. (doi:10.1002/ijc.2910570121)
- Horie K, Takakura K, Imai K, Liao S & Mori T 1992 Immunohistochemical localization of androgen receptor in the human endometrium, decidua, placenta and pathological conditions of the endometrium. *Human Reproduction* **7** 1461–1466.
- Ito K 2005 In situ estrogen metabolism and synthesis in endometrium and breast. *Acta Obstetrica et Gynaecologica Japonica* **57** 1819–1827.
- Ito K, Suzuki T, Akahira J, Moriya T, Kaneko C, Utsunomiya H, Yaegashi N, Okamura K & Sasano H 2002 Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders. *International Journal of Cancer* **99** 652–657. (doi:10.1002/ijc.10394)
- Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira J, Okamura K, Yaegashi N & Sasano H 2006 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders. *Molecular and Cellular Endocrinology* **248** 136–140. (doi:10.1016/j.mce.2005.11.038)
- Jongen VH, Briët JM, de Jong RA, Joppe E, ten Hoor KA, Boezen HM, Evans DB, Hollema H, van der Zee AG & Nijman HW 2009 Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. *International Journal of Gynecological Cancer* **19** 670–676. (doi:10.1111/igc.0b013e3181a47c25)
- Kaaks R, Lukanova A & Kurzer MS 2002 Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. *Cancer Epidemiology, Biomarkers & Prevention* **11** 1531–1543.
- Kamal AM, Bulmer JN, DeCruze SB, Stringfellow HF, Martin-Hirsch P & Hapangama DK 2016 Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival. *British Journal of Cancer* **114** 688–696. (doi:10.1038/bjc.2016.16)
- Labrie F 2015 All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. *Journal of Steroid Biochemistry and Molecular Biology* **145** 133–138. (doi:10.1016/j.jsmb.2014.06.001)
- Labrie F, Martel C & Balser J 2011 Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? *Menopause* **18** 30–43. (doi:10.1097/gme.0b013e3181e195a6)
- Lapointe J & Labrie C 2001 Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. *Endocrinology* **142** 4331–4338. (doi:10.1210/endo.142.10.8417)
- Legro RS, Kunselman AR, Miller SA & Satyaswaroop PG 2001 Role of androgens in the growth of endometrial carcinoma: an in vivo animal model. *American Journal of Obstetrics and Gynecology* **184** 303–308. (doi:10.1067/mob.2001.109734)
- Lépine J, Audet-Walsh E, Grégoire J, Têtu B, Plante M, Ménard V, Ayotte P, Brisson J, Caron P, Villeneuve L, et al. 2010 Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. *Journal of Clinical Endocrinology and Metabolism* **95** 2689–2698. (doi:10.1210/jc.2010-2648)
- Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K & Nordström B 2014 Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). *BMC Cancer* **14** 68. (doi:10.1186/1471-2407-14-68)
- Lovely LP, Appa Rao KB, Gui Y & Lessey BA 2000 Characterization of androgen receptors in a well-differentiated endometrial adenocarcinoma cell line (Ishikawa). *Journal of Steroid Biochemistry and Molecular Biology* **74** 235–241. (doi:10.1016/S0960-0760(00)00127-8)
- Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, Krogh V, Lenner P, Shore RE, Biessy C, et al. 2004 Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. *International Journal of Cancer* **108** 425–432. (doi:10.1002/ijc.11529)
- Luu-The V, Dufort I, Pelletier G & Labrie F 2001 Type 5 17beta-hydroxysteroid dehydrogenase: its role in the formation of androgens in women. *Molecular and Cellular Endocrinology* **171** 77–82. (doi:10.1016/S0303-7207(00)00425-1)
- Marshall E, Lowrey J, MacPherson S, Maybin JA, Collins F, Critchley HO & Saunders PT 2011 In silico analysis identifies a novel role for androgens in the regulation of human endometrial apoptosis. *Journal of Clinical Endocrinology and Metabolism* **96** E1746–E1755. (doi:10.1210/jc.2011-0272)
- Maruoka R, Tanabe A, Watanabe A, Nakamura K, Ashihara K, Tanaka T, Terai Y & Ohmichi M 2014 Ovarian estradiol production and lipid metabolism in postmenopausal women. *Menopause* **21** 1129–1135. (doi:10.1097/GME.0000000000000221)
- Matsumoto M, Yamaguchi Y, Seino Y, Hatakeyama A, Takei H, Niikura H, Ito K, Suzuki T, Sasano H, Yaegashi N, et al. 2008 Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. *Endocrine-Related Cancer* **15** 451–463. (doi:10.1677/ERC-07-0227)
- McGrath M, Lee IM, Hankinson SE, Kraft P, Hunter DJ, Buring J & De Vivo I 2006 Androgen receptor polymorphisms and endometrial cancer risk. *International Journal of Cancer* **118** 1261–1268. (doi:10.1002/ijc.21436)
- McNamara KM, Yoda T, Miki Y, Chanplakorn N, Wongwaisayawan S, Incharoen P, Kongdan Y, Wang L, Takagi K, Mayu T, et al. 2013

- Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. *Cancer Science* **104** 639–646. (doi:10.1111/cas.12121)
- Mertens HJ, Heineman MJ, Theunissen PH, de Jong FH & Evers JL 2001 Androgen, estrogen and progesterone receptor expression in the human uterus during the menstrual cycle. *European Journal of Obstetrics & Gynecology and Reproductive Biology* **98** 58–65. (doi:10.1016/s0301-2115(00)00554-6)
- Miki Y, Fue M, Takagi K, Hashimoto C, Tanaka S, Suzuki T & Ito K 2015 Androgen receptor and intracrine androgen signaling in endometrial carcinomas. *Receptors & Clinical Investigation* **2** e853. (doi:10.14800/rci.853)
- Naitoh K, Honjo H, Yamamoto T, Urabe M, Ogino Y, Yasumura T & Nambara T 1989 Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer. *Journal of Steroid Biochemistry* **33** 1049–1054. (doi:10.1016/0022-4731(89)90408-1)
- Pasqualini JR & Chetrite GS 1999 Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. *Journal of Steroid Biochemistry and Molecular Biology* **69** 287–292. (doi:10.1016/S0960-0760(99)00082-5)
- Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, Berman ML, Mortel R, Twigg LB, Barrett RJ, et al. 1996 Case-control study of endogenous steroid hormones and endometrial cancer. *Journal of the National Cancer Institute* **88** 1127–1135. (doi:10.1093/jnci/88.16.1127)
- Qiu M, Bao W, Wang J, Yang T, He X, Liao Y & Wan X 2014 FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer. *BMC Cancer* **14** 78. (doi:10.1186/1471-2407-14-78)
- Rauh M 2012 LC-MS/MS for protein and peptide quantification in clinical chemistry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences* **883–884** 59–67. (doi:10.1016/j.jchromb.2011.09.030)
- Recchione C, Venturelli E, Manzari A, Cavalleri A, Martinetti A & Secreto G 1995 Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. *Journal of Steroid Biochemistry and Molecular Biology* **52** 541–546. (doi:10.1016/0960-0760(95)00017-T)
- Rizner TL & Penning TM 2014 Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism. *Steroids* **79** 49–63. (doi:10.1016/j.steroids.2013.10.012)
- Rizner TL, Smuc T, Ruprecht R, Sinkovec J & Penning TM 2006 AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. *Molecular and Cellular Endocrinology* **248** 126–135. (doi:10.1016/j.mce.2005.10.009)
- Rodríguez G, Bilbao C, Ramírez R, Falcón O, León L, Chirino R, Falcón O Jr, Díaz BP, Rivero JF, Peruchó M, et al. 2006 Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer. *International Journal of Cancer* **118** 1420–1425. (doi:10.1002/ijc.21516)
- Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL & Lee RB 2000 A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecologic Oncology* **78** 212–216. (doi:10.1006/gyno.2000.5865)
- Russell DW & Wilson JD 1994 Steroid 5 alpha-reductase: two genes/two enzymes. *Annual Review of Biochemistry* **63** 25–61. (doi:10.1146/annurev.bi.63.070194.000325)
- Sasaki M, Oh BR, Dharia A, Fujimoto S & Dahiya R 2000 Inactivation of the human androgen receptor gene is associated with CpG hypermethylation in uterine endometrial cancer. *Molecular Carcinogenesis* **29** 59–66. (doi:10.1002/1098-2744(200010)29:2<59::aid-mc2>3.0.co;2-6)
- Sasano H & Harada N 1998 Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. *Endocrine Reviews* **19** 593–607. (doi:10.1210/edrv.19.5.0342)
- Sasano H, Sato S, Ito K, Yajima A, Nakamura J, Yoshihama M, Ariga K, Anderson TJ & Miller WR 1999 Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. *Endocrine-Related Cancer* **6** 197–204. (doi:10.1677/erc.0.0060197)
- Segawa T, Shozu M, Murakami K, Kasai T, Shinohara K, Nomura K, Ohno S & Inoue M 2005 Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival. *Clinical Cancer Research* **11** 2188–2194. (doi:10.1158/1078-0432.CCR-04-1859)
- Shibuya R, Suzuki T, Miki Y, Yoshida K, Moriya T, Ono K, Akahira J, Ishida T, Hirakawa H, Evans DB, et al. 2008 Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. *Endocrine-Related Cancer* **15** 113–124. (doi:10.1677/ERC-07-0092)
- Shufelt CL & Braunstein GD 2009 Safety of testosterone use in women. *Maturitas* **63** 63–66. (doi:10.1016/j.maturitas.2009.01.012)
- Siegel RL, Miller KD & Jemal A 2016 Cancer statistics, 2016. *CA: A Cancer Journal for Clinicians* **66** 7–30. (doi:10.3322/caac.21332)
- Sinreih M, Hevir N & Rizner TL 2013 Altered expression of genes involved in progesterone biosynthesis, metabolism and action in endometrial cancer. *Chemico-Biological Interactions* **202** 210–217. (doi:10.1016/j.cbi.2012.11.012)
- Smuc T & Rizner TL 2009 Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. *Molecular and Cellular Endocrinology* **301** 74–82. (doi:10.1016/j.mce.2008.09.019)
- Somboonporn W, Davis SR & National Health and Medical Research Council 2004 Testosterone effects on the breast: implications for testosterone therapy for women. *Endocrine Reviews* **25** 374–388. (doi:10.1210/er.2003-0016)
- Suzuki T, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S & Sasano H 2007 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. *International Journal of Cancer* **120** 285–291. (doi:10.1002/ijc.22317)
- Suzuki T, Miki Y, Takagi K, Hirakawa H, Moriya T, Ohuchi N & Sasano H 2010 Androgens in human breast carcinoma. *Medical Molecular Morphology* **43** 75–81. (doi:10.1007/s00795-010-0494-3)
- Takagi K, Miki Y, Nagasaki S, Hirakawa H, Onodera Y, Akahira J, Ishida T, Watanabe M, Kimijima I, Hayashi S, et al. 2010 Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. *Endocrine-Related Cancer* **17** 415–430. (doi:10.1677/ERC-09-0257)
- Takahashi-Shiga N, Utsunomiya H, Miki Y, Nagase S, Kobayashi R, Matsumoto M, Niikura H, Ito K & Yaegashi N 2009 Local biosynthesis of estrogen in human endometrial carcinoma through tumor-stromal cell interactions. *Clinical Cancer Research* **15** 6028–6034. (doi:10.1158/1078-0432.CCR-09-1013)
- Tanaka S, Miki Y, Hashimoto C, Takagi K, Doe Z, Li B, Yaegashi N, Suzuki T & Ito K 2015 The role of 5α-reductase type 1 associated with intratumoral dihydrotestosterone concentrations in human endometrial carcinoma. *Molecular and Cellular Endocrinology* **401** 56–64. (doi:10.1016/j.mce.2014.11.022)
- Thangavelu A, Hewitt MJ, Quinton ND & Duffy SR 2013 Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study. *Gynecologic Oncology* **131** 613–618. (doi:10.1016/j.ygyno.2013.09.023)
- Tuckerman EM, Okon MA, Li T & Laird SM 2000 Do androgens have a direct effect on endometrial function? An in vitro study. *Fertility and Sterility* **74** 771–779. (doi:10.1016/S0015-0282(00)00711-1)
- Utsunomiya H, Suzuki T, Kaneko C, Takeyama J, Nakamura J, Kimura K, Yoshihama M, Harada N, Ito K, Konno R, et al. 2001 The analyses of 17β-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma. *Journal of Clinical Endocrinology and Metabolism* **86** 3436–3443. (doi:10.1210/jc.86.7.3436)
- van Landeghem AA, Poortman J, Nabuurs M & Thijssen JH 1985 Endogenous concentration and subcellular distribution of estrogens

- in normal and malignant human breast tissue. *Cancer Research* **45** 2900–2906.
- Vermeulen-Meiners C, Poortman J, Haspels AA & Thijssen JH 1986 The endogenous concentration of estradiol and estrone in pathological human postmenopausal endometrium. *Journal of Steroid Biochemistry* **24** 1073–1078. (doi:10.1016/0022-4731(86)90362-6)
- Vihko P, Härkönen P, Soronen P, Törn S, Herrala A, Kurkela R, Pulkka A, Oduwole O & Isomaa V 2004 17 beta-hydroxysteroid dehydrogenases – their role in pathophysiology. *Molecular and Cellular Endocrinology* **215** 83–88. (doi:10.1016/j.mce.2003.11.021)
- Watanabe K, Sasano H, Harada N, Ozaki M, Niikura H, Sato S & Yajima A 1995 Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. *American Journal of Pathology* **146** 491–500.
- Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO & Andersson S 1993 Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. *Journal of Biological Chemistry* **268** 12964–12969.
- Yang HP, Garcia-Closas M, Lacey JV Jr, Brinton LA, Lissowska J, Peplonska B, Chanock S & Gaudet MM 2009 Genetic variation in the androgen receptor gene and endometrial cancer risk. *Cancer Epidemiology, Biomarkers & Prevention* **18** 585–589. (doi:10.1158/1055-9965.EPI-08-0677)
- Yang HP, Gonzalez Bosquet J, Li Q, Platz EA, Brinton LA, Sherman ME, Lacey JV Jr, Gaudet MM, Burdette LA, Figueroa JD, et al. 2010 Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. *Carcinogenesis* **31** 827–833. (doi:10.1093/carcin/bgp328)
- Yoda T, McNamara KM, Miki Y, Takagi M, Rai Y, Ohi Y, Sagara Y, Tamaki K, Hirakawa H, Ishida T, et al. 2014 Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast. *Cancer Science* **105** 1503–1509. (doi:10.1111/cas.12535)
- Zakharov V, Lin HK, Azzarello J, McMeekin S, Moore KN, Penning TM & Fung KM 2010 Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. *International Journal of Clinical and Experimental Pathology* **3** 608–617.
- Zang H, Sahlin L, Masironi B, Eriksson E & Lindén Hirschberg A 2007 Effects of testosterone treatment on endometrial proliferation in postmenopausal women. *Journal of Clinical Endocrinology and Metabolism* **92** 2169–2175. (doi:10.1210/jc.2006-2171)

Received in final form 17 May 2016

Accepted 10 June 2016

Accepted Preprint published online 10 June 2016